Trial Profile
Periprocedural Cangrelor in Patients With ST-Elevation Myocardial Infarction to Reduce Development of Myocardial Necrosis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2022
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 05 Mar 2020 Status changed from recruiting to discontinued.
- 14 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 Feb 2017 New trial record